文献速递糖尿病

急性与慢性刺激AMP活化蛋白激酶对调节性胰岛素分泌的相反效应

Opposing effects on regulated insulin secretion of acute vs chronic stimulation of AMP-activated protein kinase.
PubMed 文献 · Diabetologia · 2022-03-16

本研究在C57BL6/J小鼠胰岛和EndoC-βH3细胞中,用三种ADaM位点AMPK激活剂(991、PF-06409577、RA089)急性激活AMPK,并构建γ1亚基功能获得性突变(D316a)小鼠模型慢性激活AMPK。结果显示急性激活促进高糖刺激的胰岛素分泌,而慢性激活(全身或β细胞选择性)损害体内外胰岛素释放并降低糖耐量。

要点

  • 急性(1.5小时)ADaM位点AMPK激活剂991、PF-06409577或RA089在高糖浓度下稳健刺激野生型小鼠胰岛胰岛素分泌。
  • 慢性AMPK激活(全身或β细胞选择性)损害体内胰岛素释放并降低糖耐量。
  • AMPK激活对胰岛素分泌呈现复杂的时间依赖性效应,应指导AMPK调节剂的设计和未来临床使用。

核心结论

  • AMPK激活对胰岛素分泌发挥复杂的时间依赖性效应,这些观察应指导AMPK调节剂的设计和未来临床使用。

研究设计与样本

  • 在分离的C57BL6/J小鼠胰岛和EndoC-βH3细胞系中,使用三种结构不同的ADaM位点激活剂(991、PF-06409577和RA089)急性激活AMPK,这些激活剂对含β1与含β2复合物的选择性不同。
  • 构建在γ1 AMPK亚基中表达功能获得性突变(D316a)的小鼠品系,以检查全身或选择性在β细胞中慢性AMPK刺激的效应。

主要发现

  • 急性(1.5小时)用991、PF-06409577或RA089处理野生型小鼠胰岛,在高糖浓度下稳健刺激胰岛素分泌(分别为p<0.01、p<0.05和p<0.001)。
  • 尽管991(AUC,p<0.05)和RA089在最高剂量(25 μmol/l)5.59 min时(p<0.05)降低葡萄糖诱导的细胞内游离Ca2+动力学。
  • 991的效应在缺乏AMPK时被废除,但在缺乏上游激酶肝激酶B1时仍观察到,进一步提示「放大」通路。
  • 慢性激活AMPK(全身或选择性在β细胞)损害体内胰岛素释放(腹腔注射3 mmol/l葡萄糖后15 min时p<0.05)和体外胰岛素释放(胰岛与17 mmol/l葡萄糖孵育后p<0.01),并降低糖耐量(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Although targeted in extrapancreatic tissues by several drugs used to treat type 2 diabetes, the role of AMP-activated protein kinase (AMPK) in the control of insulin secretion is still debatable. Previous studies have used pharmacological activators of limited selectivity and specificity, and none has examined in primary pancreatic beta cells the actions of the latest generation of highly potent and specific activators that act via the allosteric drug and metabolite (ADaM) site. METHODS: AMPK was activated acutely in islets isolated from C57BL6/J mice, and in an EndoC-βH3 cell line, using three structurally distinct ADaM site activators (991, PF-06409577 and RA089), with varying selectivity for β1- vs β2-containing complexes. Mouse lines expressing a gain-of-function mutation in the γ1 AMPK subunit (D316a) were generated to examine the effects of chronic AMPK stimulation in the whole body, or selectively in the beta cell. RESULTS: Acute (1.5 h) treatment of wild-type mouse islets with 991, PF-06409577 or RA089 robustly stimulated insulin secretion at high glucose concentrations (p<0.01, p<0.05 and p<0.001, respectively), despite a lowering of glucose-induced intracellular free Ca2+ dynamics in response to 991 (AUC, p<0.05) and to RA089 at the highest dose (25 μmol/l) at 5.59 min (p<0.05). Although abolished in the absence of AMPK, the effects of 991 were observed in the absence of the upstream kinase, liver kinase B1, further implicating 'amplifying' pathways. In marked contrast, chronic activation of AMPK, either globally or selectively in the beta cell, achieved using a gain-of-function mutant, impaired insulin release in vivo (p<0.05 at 15 min following i.p. injection of 3 mmol/l glucose) and in vitro (p<0.01 following incubation of islets with 17 mmol/l glucose), and lowered glucose tolerance (p<0.001). CONCLUSIONS/INTERPRETATION: AMPK activation exerts complex, time-dependent effects on insulin secretion. These observations should inform the design and future clinical use of AMPK modulators.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Nguyen-Tu MS, Harris J, Martinez-Sanchez A, et al. Opposing effects on regulated insulin secretion of acute vs chronic stimulation of AMP-activated protein kinase. Diabetologia. 2022. PMID: 35294578. doi:10.1007/s00125-022-05673-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。